Dolutegravir for children with HIV-associated tuberculosis

Abstract

In The Lancet HIV, Anna Turkova and colleagues1 report the findings of a pharmacokinetic and safety substudy nested within the ODYSSEY trial, which provides evidence that twice-daily dolutegravir dosing is safe and effective when used with rifampicin-containing tuberculosis (TB) treatment in children with HIV-associated TB. Their findings support the 2021 WHO HIV recommendations for once-daily dolutegravir as a component of first-line and second-line HIV treatment from age 4 weeks or older, and twice-daily dosing during treatment with rifampicin-based therapy for TB coinfection.